Lanifibranor definition
Examples of Lanifibranor in a sentence
Lanifibranor is currently being evaluated in a pivotal Phase III clinical trial.
Lanifibranor improved all histological features of steatohepatitis in mice, including liver fibrosis, thereby combing and exceeding specific effects of the single PPAR agonists.
Lanifibranor for the treatment of NASHRandomization of the first patient in the United States in the NATIVE Phase IIb study in non-alcoholic steatohepatitis (NASH) with lanifibranor.As part of its NATIVE Phase IIb clinical study to investigate lanifibranor in the treatment of NASH, Inventiva randomized its first patient in the United States in February 2019.
Lanifibranor or selective PPARα (fenofibrate), PPARγ (pioglitazone) and PPARδ (GW501516) agonists were administered in mice with choline-deficient, amino acid-defined high-fat diet-induced steatohepatitis.
Recently published positive data from Inventiva demonstrated statistically significant efficacy in both FDA preferred NASH endpoints [Figure 3].62Regardless, mean weight gain of 2.7kg was observed at the highest dose of 1200mg, and 2.4kg at 800mg, along with 14 patients experiencing oedema (12 of those received Lanifibranor).
The project finances the Borrower’s R&D expenses over the next 3 year, mainly related to the development of Lanifibranor, Odiparcil and YaP-Tead programs, as well as programs still at pre-clinical stages and potential new leads (non-clinical and clinical studies, product manufacturing, related regulatory expenses, and related G&A expenses).
Lanifibranor attenuated palmitic acid-induced inflammatory activation of primary macrophages in vitro in a PPARδ-dependent fashion.
Lanifibranor is a pan-PPARagonist, while Elafibranor targets PPAR alpha and delta, and Seladelpar is only delta subtype selective.
Price BEL20 (rebased)-21Jan-22May-22Source: KBC SecuritiesSource: Refinitiv DatastreamKBC Securities NV is regulated by FSMARefer to important disclosures, disclaimers and analyst certification at the end of this reportInventiva also announced that it has entered into an agreement with Sino Biopharm, via its subsidiary Chia Tai-Tianqing Pharmaceutical Group Co., Ltd (CTTQ), to bring Lanifibranor to the Chinese market.
Lanifibranor is an orally-available small molecule that acts to induce anti-fibrotic, anti-inflammatory and beneficial metabolic changes in the body by activating all three peroxisome proliferator-activated receptor isoforms, PPAR, and .